UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Kronik Hepatit B Tedavisinde Kullanilan Tenofovir Disoproksil Fumarat ve Entekavirin Vestibulokoklear Toksisitesinin Klinik Olarak Arastirilmasi

Mediterranean journal of infection, microbes & antimicrobials, 2024-01, Vol.13, p.73

2024

Volltextzugriff (PDF)

LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS (LAMIVUDINI ET TENOFOVIRI DISOPROXILI FUMARATI COMPRESSI)/LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS (LAMIVUDINI ET TENOFOVIRI DISOPROX ILI FUMARATI COMPRESSI)

WHO drug information, 2022-12, Vol.36 (4), p.905

2022

Volltextzugriff (PDF)

TENOFOVIR DISOPROXIL FUMARATE TABLETS (TENOFOVIRI DISOPROXILI FUMARATI COMPRESSI)/TENOFOVIR DISOPROXIL FUMARATE TABLETS (TENOFOVIRI DISOPROXILI FUMARATI COMPRESSI)

WHO drug information, 2022-12, Vol.36 (4), p.914

2022

Volltextzugriff (PDF)

Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)

Biochemical pharmacology, 2016-11, Vol.119, p.1-7

De Clercq, Erik

2016

Volltextzugriff (PDF)

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B

Journal of gastroenterology and hepatology, 2024-08, Vol.39 (8), p.1673-1683

2024

Volltextzugriff (PDF)

Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women

Science (American Association for the Advancement of Science), 2017-06, Vol.356 (6341), p.938-945

2017

Volltextzugriff (PDF)

Development and validation of an LC–MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid

Journal of pharmaceutical and biomedical analysis, 2018-07, Vol.156, p.163-169

2018

Volltextzugriff (PDF)

Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B: week 144 results from a real‐world, multi‐centre cohort study

Alimentary pharmacology & therapeutics, 2022-08, Vol.56 (4), p.713-722

2022

Volltextzugriff (PDF)

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study

Journal of hepatology, 2017-11, Vol.67 (5), p.918-924

2017

Volltextzugriff (PDF)

A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017

Infection, 2019-02, Vol.47 (1), p.95-102

2019

Volltextzugriff (PDF)

Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate

Clinical gastroenterology and hepatology, 2022-02, Vol.20 (2), p.427-437.e5

2022

Volltextzugriff (PDF)

Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide‐based ART

Drug testing and analysis, 2021-07, Vol.13 (7), p.1354-1370

2021

Volltextzugriff (PDF)

Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles

Nature communications, 2021-09, Vol.12 (1), p.5458-16, Article 5458

2021

Volltextzugriff (PDF)

Brief Report: No Difference in Urine Tenofovir Levels in Patients Living With HIV on Unboosted Versus Dose-Adjusted Boosted Tenofovir Alafenamide

Journal of acquired immune deficiency syndromes (1999), 2021-09, Vol.88 (1), p.57-60

2021

Volltextzugriff (PDF)

Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B

Medicine (Baltimore), 2024-05, Vol.103 (20), p.e37953

2024

Volltextzugriff (PDF)

Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update

Hepatology research, 2020-08, Vol.50 (8), p.892-923

Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology

2020

Volltextzugriff (PDF)

Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies

Journal of acquired immune deficiency syndromes (1999), 2023-11, Vol.94 (3), p.e9-e12

2023

Volltextzugriff (PDF)

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

The New England journal of medicine, 2015-12, Vol.373 (23), p.2237-2246

2015

Volltextzugriff (PDF)

Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model

Pharmaceutical research, 2017-12, Vol.34 (12), p.2749-2755

2017

Volltextzugriff (PDF)

Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement

JAMA : the journal of the American Medical Association, 2019-06, Vol.321 (22), p.2203

2019

Volltextzugriff (PDF)

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles

Clinical and molecular hepatology, 2022-04, Vol.28 (2), p.181

2022

Volltextzugriff (PDF)

Stability behaviour of antiretroviral drugs and their combinations. 4: Characterization of degradation products of tenofovir alafenamide fumarate and comparison of its degradation and stability behaviour with tenofovir disoproxil fumarate

Journal of pharmaceutical and biomedical analysis, 2016-11, Vol.131, p.146-155

2016

Volltextzugriff (PDF)

Metabolic effects and cardiovascular disease risks of antiviral treatments in patients with chronic hepatitis B

Journal of medical virology, 2024-07, Vol.96 (7), p.e29760-n/a

2024

Volltextzugriff (PDF)

Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B

Journal of viral hepatitis, 2021-11, Vol.28 (11), p.1570-1578

2021

Volltextzugriff (PDF)

1 – 25 von 6.606

Suche als RSS-Feed

Aktive Filter

ThemaImmunology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(5.693)
Mit Volltextzugriff
(5.396)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

13 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Tenofovir
(5.160)
Science & Technology
(4.776)
Life Sciences & Biomedicine
(4.333)
Humans
(4.162)
Hiv
(2.343)
Female
(2.167)
Human Immunodeficiency Virus
(2.125)
Adenine - Analogs & Derivatives
(2.062)
Male
(2.042)
Hiv Infections - Drug Therapy
(1.905)
Adult
(1.729)
Infectious Diseases
(1.526)
Pharmacology & Pharmacy
(1.432)
Antiretroviral Drugs
(1.414)
Middle Aged
(1.321)
Anti-Hiv Agents - Therapeutic Use
(1.261)
Emtricitabine
(1.218)
Adenine - Therapeutic Use
(1.207)
Hepatitis B
(1.195)
Antiviral Agents
(993)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(4.440)
EZB Electronic Journals Library
(3.567)
Journals@Ovid Full Text
(2.543)
Ingenta.com
(2.543)
IngentaConnect Journals
(1.686)
Wiley Online Library
(1.009)
SpringerLink_现刊
(890)
ScienceDirect Journals (5 years ago - present)
(825)
Wiley Online Library Full Collection 2018
(814)
Publisher or Other Site
(716)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(468)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(368)
Taylor & Francis Journals
(354)
Taylor & Francis
(320)
Nexis Uni
(310)
SAGE Journals
(281)
Taylor & Francis:Master (3349 titles)
(239)
Oxford Journals
(200)
Oxford Journals 2020 Medicine
(178)
Sociological Abstracts
(122)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(18)
... seit 90 Tagen
(53)

Menü

Weitere Dienste

Einstellungen

Kronik Hepatit B Tedavisinde Kullanilan Tenofovir Disoproksil Fumarat ve Entekavirin Vestibulokoklear Toksisitesinin Klinik Olarak Arastirilmasi

LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS (LAMIVUDINI ET TENOFOVIRI DISOPROXILI FUMARATI COMPRESSI)/LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS (LAMIVUDINI ET TENOFOVIRI DISOPROX ILI FUMARATI COMPRESSI)

TENOFOVIR DISOPROXIL FUMARATE TABLETS (TENOFOVIRI DISOPROXILI FUMARATI COMPRESSI)/TENOFOVIR DISOPROXIL FUMARATE TABLETS (TENOFOVIRI DISOPROXILI FUMARATI COMPRESSI)

Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B

Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women

Development and validation of an LC–MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid

Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B: week 144 results from a real‐world, multi‐centre cohort study

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study

A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017

Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate

Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide‐based ART

Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles

Brief Report: No Difference in Urine Tenofovir Levels in Patients Living With HIV on Unboosted Versus Dose-Adjusted Boosted Tenofovir Alafenamide

Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B

Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update

Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model

Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles

Stability behaviour of antiretroviral drugs and their combinations. 4: Characterization of degradation products of tenofovir alafenamide fumarate and comparison of its degradation and stability behaviour with tenofovir disoproxil fumarate

Metabolic effects and cardiovascular disease risks of antiviral treatments in patients with chronic hepatitis B

Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B

Aktive Filter

Suchergebnisse filtern